Hs-CRP in stroke: A meta-analysis

Clinica Chimica Acta

Volumn 453, Issue , 2016, Pages 21-27

  Zhou, Yongjing ^a   Han, Wei ^b   Gong, Dandan ^a   Man, Changfeng ^a   Fan, Yu ^a  

^a JIANGSU UNIVERSITY   (China)

^b Shenyang Children's Hospital   (China)

Author keywords

Hemorrhagic stroke; High sensitivity C reactive protein; Ischemic stroke; Meta analysis; Stroke

Indexed keywords

GLOBULIN; HIGH SENSITIVITY C REACTIVE PROTEIN; PLASMA PROTEIN; UNCLASSIFIED DRUG; C REACTIVE PROTEIN;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; COMPLICATION; META ANALYSIS; METABOLISM;

BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBRAL HEMORRHAGE; HUMANS; STROKE;

EID: 84949559780     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.11.027     Document Type: Review

References (43)

1. Donnan G.A., Fisher M., Macleod M., Davis S.M. Stroke. Lancet 2008, 371:1612-1623.
2. Flynn R.W., MacWalter R.S., Doney A.S. The cost of cerebral ischaemia. Neuropharmacology 2008, 55:250-256.
3. Shiber J.R., Fontane E., Adewale A. Stroke registry: hemorrhagic vs ischemic strokes. Am. J. Emerg. Med. 2010, 28:331-333.
4. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
5. Corrado E., Rizzo M., Coppola G., et al. An update on the role of markers of inflammation in atherosclerosis. J. Atheroscler. Thromb. 2010, 17:1-11.
6. Musunuru K., Kral B.G., Blumenthal R.S., et al. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:621-635.
7. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
8. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997, 336:973-979.
9. Cao J.J., Thach C., Manolio T.A., et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 2003, 108:166-170.
10. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch. Intern. Med. 2005, 165:2479-2484.
11. Sattar N., Murray H.M., McConnachie A., et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007, 115:981-989.
12. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., Fowkes F.G. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007, 115:2119-2127.
13. Makita S., Nakamura M., Satoh K., et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis 2009, 204:234-238.
14. Andersson J., Johansson L., Ladenvall P., et al. C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study. Cerebrovasc. Dis. 2009, 27:544-551.
15. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322.
16. Wakugawa Y., Kiyohara Y., Tanizaki Y., et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke 2006, 37:27-32.
17. Bos M.J., Schipper C.M., Koudstaal P.J., Witteman J.C., Hofman A., Breteler M.M. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation 2006, 114:1591-1598.
18. Elkind M.S., Luna J.M., Moon Y.P., et al. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology 2009, 73:1300-1307.
19. Iso H., Noda H., Ikeda A., et al. The impact of C-reactive protein on risk of stroke, stroke subtypes, and ischemic heart disease in middle-aged Japanese: the Japan public health center-based study. J. Atheroscler. Thromb. 2012, 19:756-766.
20. Kelley-Hedgepeth A., Lloyd-Jones D.M., Colvin A., et al. Ethnic differences in C-reactive protein concentrations. Clin. Chem. 2008, 54:1027-1037.
21. Ahonen T.M., Kautiainen H.J., Keinanen-Kiukaanniemi S.M., Kumpusalo E.A., Vanhala M.J. Gender difference among smoking, adiponectin, and high-sensitivity C-reactive protein. Am. J. Prev. Med. 2008, 35:598-601.
22. Kaptoge S., Di Angelantonio E., Lowe G., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
23. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151:264-269. W264.
24. Iso H., Rexrode K., Hennekens C.H., Manson J.E. Application of computer tomography-oriented criteria for stroke subtype classification in a prospective study. Ann. Epidemiol. 2000, 10:81-87.
25. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed April 6, 2014).
26. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
27. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
28. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
29. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 1999, 340:1801-1811.
30. Walsh B.W., Paul S., Wild R.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 2000, 85:214-218.
31. Roudbary S.A., Saadat F., Forghanparast K., Sohrabnejad R. Serum C-reactive protein level as a biomarker for differentiation of ischemic from hemorrhagic stroke. Acta Med. Iran. 2011, 49:149-152.
32. Purroy F., Montaner J., Molina C.A., et al. C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol. Scand. 2007, 115:60-66.
33. Arenillas J.F., Alvarez-Sabin J., Molina C.A., et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003, 34:2463-2468.
34. Kaplan R.C., McGinn A.P., Baird A.E., et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study. J. Stroke Cerebrovasc. Dis. 2008, 17:344-355.
35. Legein B., Temmerman L., Biessen E.A., Lutgens E. Inflammation and immune system interactions in atherosclerosis. Cell. Mol. Life Sci. 2013, 70:3847-3869.
36. Rosenfeld M.E. Inflammation and atherosclerosis: direct versus indirect mechanisms. Curr. Opin. Pharmacol. 2013, 13:154-160.
37. Businaro R., Tagliani A., Buttari B., et al. Cellular and molecular players in the atherosclerotic plaque progression. Ann. N. Y. Acad. Sci. 2012, 1262:134-141.
38. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int. J. Cardiol. 2013, 168:5126-5134.
39. Caplan L.R. Intracerebral haemorrhage. Lancet 1992, 339:656-658.
40. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2167-2176.
41. Verhagen S.N., Wassink A.M., van der Graaf Y., Visseren F.L. C-reactive protein and incident diabetes in patients with arterial disease. Eur. J. Clin. Investig. 2013, 43:1052-1059.
42. Schillaci G., Pirro M. C-reactive protein in hypertension: clinical significance and predictive value. Nutr. Metab. Cardiovasc. Dis. 2006, 16:500-508.
43. Lu H.H., Guo Z.R., Hu X.S., Wu M., Zhou M.H., Zhou Z.Y. The prospective study of association between C-reactive protein and hypertension in community population. Zhonghua Yu Fang Yi Xue Za Zhi 2013, 47:1026-1030.